Petros Pharmaceuticals Stock Current Liabilities

PTPI Stock  USD 0.28  0.01  3.70%   
Petros Pharmaceuticals fundamentals help investors to digest information that contributes to Petros Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Petros Stock. The fundamental analysis module provides a way to measure Petros Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Petros Pharmaceuticals stock.
The current Total Current Liabilities is estimated to decrease to about 10.2 M. The current Non Current Liabilities Total is estimated to decrease to about 8.8 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Petros Pharmaceuticals Company Current Liabilities Analysis

Petros Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

 = 

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

Petros Current Liabilities Driver Correlations

Understanding the fundamental principles of building solid financial models for Petros Pharmaceuticals is extremely important. It helps to project a fair market value of Petros Stock properly, considering its historical fundamentals such as Current Liabilities. Since Petros Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Petros Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Petros Pharmaceuticals' interrelated accounts and indicators.
-0.950.35-0.610.67-0.21-0.550.79-0.96-0.860.29-0.90.95-0.93-0.970.99-0.93-0.94-0.960.63
-0.95-0.430.51-0.54-0.070.58-0.680.890.79-0.240.87-0.880.870.94-0.950.850.930.94-0.66
0.35-0.430.380.690.310.460.63-0.17-0.690.550.010.59-0.1-0.510.23-0.15-0.1-0.15-0.08
-0.610.510.38-0.090.190.74-0.390.80.310.10.84-0.420.850.41-0.690.840.70.71-0.5
0.67-0.540.69-0.09-0.330.220.88-0.55-0.930.41-0.320.81-0.49-0.730.55-0.54-0.42-0.470.27
-0.21-0.070.310.19-0.330.08-0.150.160.17-0.070.15-0.180.160.19-0.180.160.170.17-0.1
-0.550.580.460.740.220.080.020.630.060.250.81-0.270.670.42-0.670.60.780.74-0.66
0.79-0.680.63-0.390.88-0.150.02-0.76-0.950.5-0.570.91-0.72-0.790.69-0.77-0.56-0.620.21
-0.960.89-0.170.8-0.550.160.63-0.760.78-0.170.96-0.861.00.86-0.971.00.930.95-0.64
-0.860.79-0.690.31-0.930.170.06-0.950.78-0.490.6-0.960.720.9-0.770.760.660.72-0.37
0.29-0.240.550.10.41-0.070.250.5-0.17-0.49-0.160.51-0.13-0.40.16-0.17-0.03-0.19-0.51
-0.90.870.010.84-0.320.150.81-0.570.960.6-0.16-0.760.970.8-0.950.940.950.97-0.62
0.95-0.880.59-0.420.81-0.18-0.270.91-0.86-0.960.51-0.76-0.82-0.970.88-0.84-0.79-0.840.4
-0.930.87-0.10.85-0.490.160.67-0.721.00.72-0.130.97-0.820.83-0.961.00.930.94-0.65
-0.970.94-0.510.41-0.730.190.42-0.790.860.9-0.40.8-0.970.83-0.930.820.880.91-0.55
0.99-0.950.23-0.690.55-0.18-0.670.69-0.97-0.770.16-0.950.88-0.96-0.93-0.94-0.98-0.990.71
-0.930.85-0.150.84-0.540.160.6-0.771.00.76-0.170.94-0.841.00.82-0.940.90.92-0.6
-0.940.93-0.10.7-0.420.170.78-0.560.930.66-0.030.95-0.790.930.88-0.980.90.98-0.78
-0.960.94-0.150.71-0.470.170.74-0.620.950.72-0.190.97-0.840.940.91-0.990.920.98-0.7
0.63-0.66-0.08-0.50.27-0.1-0.660.21-0.64-0.37-0.51-0.620.4-0.65-0.550.71-0.6-0.78-0.7
Click cells to compare fundamentals

Petros Current Liabilities Historical Pattern

Today, most investors in Petros Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Petros Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Petros Pharmaceuticals current liabilities as a starting point in their analysis.
   Petros Pharmaceuticals Current Liabilities   
       Timeline  
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition

Petros Total Current Liabilities

Total Current Liabilities

10.23 Million

As of now, Petros Pharmaceuticals' Total Current Liabilities is decreasing as compared to previous years.
In accordance with the recently published financial statements, Petros Pharmaceuticals has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module

Petros Fundamentals

About Petros Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Petros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Petros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Petros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:
Check out Petros Pharmaceuticals Piotroski F Score and Petros Pharmaceuticals Altman Z Score analysis.
For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.80)
Revenue Per Share
0.99
Quarterly Revenue Growth
(0.29)
Return On Assets
(0.31)
Return On Equity
(0.64)
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.